Mythic Imagination Institute

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Retrieved on: 
Thursday, October 12, 2023
PIK3CD, TALEN, Euronext Growth, Research, Mythic Imagination Institute, Vaccine, Management, Cellectis

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.

Key Points: 
  • NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.
  • The research work described in this article was jointly conducted by Imagine Institute and Cellectis teams.

Mythics, LLC Announces Partnership with Virginia Wesleyan University for Oracle Student Cloud Implementation

Retrieved on: 
Thursday, June 22, 2023
Partnership, University, Education, Virginia Wesleyan University, Mythic Imagination Institute, Student, Oracle Cloud, Pleasure, Faculty, Wesleyan theology, HCM, Software, Nursing, Management, Cloud, Oracle

"We see Oracle Student Cloud as a transformational leap to a cloud-native solution that will benefit our faculty and students far into the future," said Greg Skinner, Chief Information Officer at Virginia Wesleyan University.

Key Points: 
  • "We see Oracle Student Cloud as a transformational leap to a cloud-native solution that will benefit our faculty and students far into the future," said Greg Skinner, Chief Information Officer at Virginia Wesleyan University.
  • Virginia Wesleyan University initially selected Oracle and Mythics as their partners in the summer of 2022 to transform their Finance and Human Resources operations leveraging Oracle Fusion ERP and HCM Cloud.
  • "We're excited to be helping support the effort, and we look forward to a lasting partnership with Virginia Wesleyan University."
  • Mythics LLC is committed to helping clients like Virginia Wesleyan University leverage the full potential of Oracle Cloud solutions to achieve their business objectives and drive innovation.

Mechanisms Underlying Autoimmunity in Down Syndrome Revealed

Retrieved on: 
Wednesday, February 22, 2023
JAK, Autoimmunity, Skin, Marc, Therapy, Doctor of Philosophy, Volunteering, Integrin alpha X, MD, T cell, Immune system, Hair loss, Infection, Immune tolerance, Viral, Disease, Immunity, Nature, Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Patient, Icahn School of Medicine at Mount Sinai, Inflammation, Mythic Imagination Institute, NIH, Division, NIH Intramural Research Program, Disorder, Mount Sinai, National Institute of Allergy and Infectious Diseases, Cytokine, Down syndrome, Rockefeller University, Thyroid, Person, CD4, Vaccine, Pharmaceutical industry, Medical device

NEW YORK, Feb. 22, 2023 /PRNewswire-PRWeb/ -- Scientists at the Icahn School of Medicine at Mount Sinai in New York have identified which parts of the immune system go awry and contribute to autoimmune diseases in individuals with Down syndrome. The findings published in the February 22 online issue of Nature [DOI: https://doi.org/10.1038/s41586-023-05736-y .

Key Points: 
  • Studying lab specimens from volunteers with Down syndrome, the investigators identified cytokines and a B cell subtype—key players in the adaptive immune response—as the potential culprits for most autoimmunity in people with the disorder.
  • Strikingly, the researchers found that many people with Down syndrome are in a perpetual state of inflammation comparable to those without Down syndrome who are in intensive care with an acute infection.
  • Among other issues, people with Down syndrome suffer from autoimmunity, including hair loss, skin, gut, and thyroid problems.
  • The paper is titled "Autoimmunity in Down syndrome via cytokines, CD4 T Cells, and CD11c + B cells."

Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Company, Pharma, Society, Mythic Imagination Institute, Date, Congress, Lymphoma, Inhibitor, IND, Saint-Genis-Pouilly, Mantle cell lymphoma, CHEK1, Multiple myeloma, ATR, Lymphatic system, Date and time notation in the United Kingdom, Hematology, Time, Cancer, CTA, Pharmaceutical industry, Fine chemical, Idinvest Partners

Step Pharma and collaborators will present two posters on STP938, its potent and highly selective small molecule inhibitor of CTPS1, reporting its potential as a targeted therapeutic for the treatment of Mantle Cell Lymphoma and Multiple Myeloma.

Key Points: 
  • Step Pharma and collaborators will present two posters on STP938, its potent and highly selective small molecule inhibitor of CTPS1, reporting its potential as a targeted therapeutic for the treatment of Mantle Cell Lymphoma and Multiple Myeloma.
  • The Company is the world leader in CTPS1 inhibition, a new approach with the potential to yield highly selective, safe and effective cancer treatments for both blood cancers and solid tumours.
  • STP938 has the potential to be the backbone of a multitude of cancer therapies as well as a potent monotherapy for hard-to-treat blood cancers.
  • Step Pharma was founded in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour.

Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas

Retrieved on: 
Monday, October 24, 2022
Pharma, Saint-Genis-Pouilly, Mythic Imagination Institute, IND, Lymphoma, Lymphatic system, Cancer, Company, Adult, CTA, Safety, Pharmaceutical industry, Fine chemical, Idinvest Partners

The primary objective in Phase I is to assess the safety and tolerability of STP938.

Key Points: 
  • The primary objective in Phase I is to assess the safety and tolerability of STP938.
  • Brian Schwartz, Chief Medical Officer of Step Pharma, commented: We are developing STP938, a highly selective, first-in-class treatment based on ground-breaking genetics.
  • The dosing of the first patient into our Phase 1/2 trial is an important step to identify an optimal dose to take forward into further clinical development for relapsed/ refractory T cell and B cell lymphomas.
  • By targeting CTPS1, Step Pharma has unlocked the ability to selectively target the de novo pyrimidine synthesis pathway in cancer cells.

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers

Retrieved on: 
Thursday, October 13, 2022
Doctor of Pharmacy, HSCT, Risk, Mythic Imagination Institute, Population, Haematopoietic system, Infection, Institute, UCB, GVHD, Patient, Foresight, Hospital, Hematology, Lymphatic system, AP-HP, Research, EDS, Transplant, Immunity (medical), Immune system, Doctor of Philosophy, CHU, Principal, Toxicity, Stem cell, Adult, University, Safety, Hematopoietic stem cell transplantation, Survival, Physiology, Immunodeficiency, ICAN, Immune reconstitution inflammatory syndrome, Travel, SAS, Vaccine, Pharmaceutical industry, Medical imaging, MD

No safety-related issues or dose limiting toxicity have been reported in the first patient enrolled in the trial to date.

Key Points: 
  • No safety-related issues or dose limiting toxicity have been reported in the first patient enrolled in the trial to date.
  • The leading hospital and university centre (CHU) in Europe, Greater Paris University Hospitals and its 38 hospitals are organised into six hospital-university groups (AP-HP.
  • In 2015, Greater Paris University Hospitals also founded the Greater Paris University Hospitals Research Foundation to support the biomedical and health research performed in all its hospitals.
  • Smart Immunes partners include Memorial Sloan Kettering in New York and Greater Paris University Hospitals (AP-HP).

Step Pharma Progresses into Oncology Clinical Trials with STP938, the World’s Most Advanced CTPS1 Inhibitor

Retrieved on: 
Thursday, July 28, 2022
Mature T-cell lymphoma, DNA, Patient, Saint-Genis-Pouilly, Health care, MHRA, Food, Mythic Imagination Institute, CTA, Adult, Safety, Lymphoma, Cancer, Drug discovery, Pharma, FDA, Company, Blood, Medicines and Healthcare products Regulatory Agency, Pharmacokinetics, Lymphatic system, Criticism of the Food and Drug Administration, IND, Fine chemical, Pharmaceutical industry, Medical imaging, Idinvest Partners

Step Pharma is pioneering a novel class of oral drugs that specifically inhibits nucleotide synthesis and the enzyme cytidine triphosphate synthase 1 (CTPS1) in particular, originally identified as an essential gene for lymphocyte proliferation.

Key Points: 
  • Step Pharma is pioneering a novel class of oral drugs that specifically inhibits nucleotide synthesis and the enzyme cytidine triphosphate synthase 1 (CTPS1) in particular, originally identified as an essential gene for lymphocyte proliferation.
  • By targeting CTPS1, Step Pharma has unlocked the ability to selectively target the de novo pyrimidine synthesis pathway in cancer cells.
  • Step Pharmas goal is to bring about a step change in how cancer is treated with targeted therapies that kill cancer cells and leave healthy cells unharmed.
  • Step Pharma was founded in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour.

Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022

Retrieved on: 
Friday, May 20, 2022
Cancer, Mythic Imagination Institute, Investigational New Drug, NSG, Company, Doctor of Pharmacy, Acute leukemia, Disease, Infection, CCR7, American, HSCT, Doctor of Philosophy, AML, Patient, ILC, CXCR4, Lymphatic system, Graft-versus-host disease, Adult, Mortality, SCID, Cell, Research, Gene, FDA, Mouse, Imagine, Allotransplantation, IND, Trial, NK, Virus, Program, Leukemia, CCR9, CD161, Prognosis, Immunodeficiency, ALL, Immune system, GLOBE, Vaccine, Dietary supplement, MD

This research provides further evidence that our lymphoid progenitors have a plasticity that allows them to differentiate into both T cells and NK cells.

Key Points: 
  • This research provides further evidence that our lymphoid progenitors have a plasticity that allows them to differentiate into both T cells and NK cells.
  • Innate lymphoid cells (ILCs) are innate counterparts of T cells that contribute to immune responses by secreting effector cytokines and regulating the functions of other innate and adaptive immune cells.
  • Through its patented ex vivo lymphoid niche technology, Smart Immune develops a thymus empowered T cell therapy platform called ProTcell.
  • The Smart Immune ProTcell platform generates allogenic T-cell progenitors that provide fully functional polyclonal T-cells within 3 months through thymic education.

eureKARE successfully hosts inaugural SynBio Day and EureKAWARDS

Retrieved on: 
Friday, November 19, 2021
MSD, CEO, Technology, Physics, Industry, Company, European Patent Convention, Biology, Genomics, Synthetic biology, Imperial College London, Therapy, Mythic Imagination Institute, Nastassia Novikava, Scientific jury selection, Policy, Research, Microbiome, CBO, Biotechnology, Financial Times, Weizmann Institute of Science, SynBio, Lists of diseases, Associate, IDC, Government procurement in the European Union, Maastricht University, Pharmaceutical industry

eureKARE would like to extend its thanks to all the attendees of the inaugural SynBio Day and to our partners, Potter Clarkson, ERS Genomics and Neighborhood VCLS Innovation Center, for contributing to the success of the event.

Key Points: 
  • eureKARE would like to extend its thanks to all the attendees of the inaugural SynBio Day and to our partners, Potter Clarkson, ERS Genomics and Neighborhood VCLS Innovation Center, for contributing to the success of the event.
  • The eureKARE SynBio Day also marked the culmination of the inaugural eureKAWARDS pitch contest, which searched for innovative start-up ideas in synthetic biology from Europe, the UK, and Israel.
  • Rodolphe Besserve, eureKARE CEO, commented: I am delighted by the success of our first ever SynBio Day which exceeded our expectations.
  • We hope to continue contributing to the field and I am already looking forward to SynBio Day 2022.

Step Pharma Appoints Experienced Cancer Drug Developer Adrian Senderowicz to Board of Directors

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Constellation, School, Patient, Icahn School of Medicine at Mount Sinai, Degenerative disease, Mythic Imagination Institute, Board of directors, Kurma, DNA, Mount Sinai, Puma, MD, Board, Puma Biotechnology, CDER, Lymphoma, CEO, Universidad, Program, Internal medicine, Growth, Cell division, AstraZeneca, Biotechnology, Drug development, National, NCI, Pharma, Leukemia, CTP, National Cancer Institute, Pharmaceutical industry, Fine chemical

Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, announced today the appointment of Dr. Adrian Senderowicz to its Board of Directors.

Key Points: 
  • Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, announced today the appointment of Dr. Adrian Senderowicz to its Board of Directors.
  • Dr. Senderowicz is a board-certified medical oncologist with 30 years of experience in drug development and commercialization.
  • Adrian has phenomenal expertise in cancer drug development having led numerous oncology clinical trials and also brings regulatory agency experience, said Andrew Parker, CEO of Step Pharma.
  • Wed like to welcome him to the Board and look forward to working closely with him as we move forward into clinical studies.